Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of three abstracts for presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentations include:

1. An oral presentation on the phase 2 LuminICE-203 study of acimtamig in combination with AlloNK® (AB-101) for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30.

2. Two poster presentations on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC): one focusing on EGFR-expressing NSCLC without driver mutations, and another on NSCLC with EGFR kinase domain mutations. Both posters will be presented on June 2.

The full abstracts will be published online on May 22, 2025.

Positive

• Acceptance of oral presentation for phase 2 LuminICE-203 study indicates significant clinical progress
• Multiple presentation formats (oral and posters) demonstrate broad clinical development program
• Diverse cancer indications (lymphoma and NSCLC) show pipeline expansion

Negative

• None.

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE^®) acimtamig in combination with AlloNK^® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.

Details of the acimtamig oral presentation and AFM24 poster presentations are as follows:

Abstract Title & Number	Date & Time	Session Type & Title
Results from the completed dose-finding part of a phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203) Abstract Number for Publication: 7008	May 30, 2025 2:45 PM-5:45 PM CDT	Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study Abstract Number for Publication: 2609	June 2, 2025 1:30 PM-4:30 PM CDT	Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 256
Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study Abstract Number for Publication: 2610	June 2, 2025 1:30 PM-4:30 PM CDT	Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 257

The full abstracts will be published online on May 22, 2025.

More details about the programs for the 2025 ASCO Annual Meeting are available online at Attend | ASCO Annual Meeting.

About Affimed N.V. 

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE^®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE^® are generated on the Company’s proprietary ROCK^® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE^® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com. 

Investor Relations Contact

Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

Media Contact

Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com

FAQ

What clinical trial results will Affimed (AFMD) present at ASCO 2025?

Affimed will present results from the LuminICE-203 phase 2 study of acimtamig/AlloNK combination for Hodgkin lymphoma, and two studies of AFM24/atezolizumab combination for different NSCLC patient populations.

When will Affimed's (AFMD) ASCO 2025 abstracts be published?

The full abstracts will be published online on May 22, 2025.

What are the different NSCLC patient populations in Affimed's (AFMD) AFM24 studies?

The studies focus on patients with EGFR-expressing NSCLC without driver mutations and patients with NSCLC with EGFR kinase domain mutations.

What is the format and timing of Affimed's (AFMD) presentations at ASCO 2025?

An oral presentation on May 30 for the LuminICE-203 study, and two poster presentations on June 2 for the AFM24 studies.